• Akari Therapeutics filed a late notice for its Form 10-Q for the quarter ended March 31, 2026, citing work tied to a previously announced public offering and related disclosures.
• The filing is expected within the SEC’s five-calendar-day extension period under Rule 12b-25.
• The quarterly results are expected to show a significant change from the prior-year period due to a material non-cash impairment charge triggered by a sustained decline in market price and market capitalization versus net asset carrying value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-024230), on May 18, 2026, and is solely responsible for the information contained therein.